Browse > Article
http://dx.doi.org/10.4062/biomolther.2016.153

Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes  

Han, Kyoung-Moon (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Ahn, Sun-Young (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Seo, Hyewon (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Yun, Jaesuk (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Cha, Hye Jin (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Shin, Ji-Soon (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Kim, Young-Hoon (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Kim, Hyungsoo (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Park, Hye-kyung (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Lee, Yong-Moon (College of Pharmacy, Chungbuk National University)
Publication Information
Biomolecules & Therapeutics / v.25, no.3, 2017 , pp. 288-295 More about this Journal
Abstract
The incidence of polypharmacy-which can result in drug-drug interactions-has increased in recent years. Drug-metabolizing enzymes and drug transporters are important polypharmacy modulators. In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro. HEK293 cells and primary human hepatocytes overexpressing the target genes were treated with bosentan and various concentrations of rifampin, which decreased the uptake activities of OATP transporters in a dose-dependent manner. In primary human hepatocytes, CYP2C9 and CYP3A4 gene expression and activities decreased upon treatment with $20{\mu}M$ $bosentan+200{\mu}M$ rifampin. Rifampin also reduced gene expression of OATP1B1, OATP1B3, and OATP2B1 transporter, and inhibited bosentan influx in human hepatocytes at increasing concentrations. These results confirm rifampin- and bosentan-induced interactions between OATP transporters and CYP450.
Keywords
Drug-drug interaction; CYP450; OATP transporters; Rifampin; Bosentan;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Sasayama, S., Kunieda, T., Tomoike, H., Matsuzaki, M., Shirato, K., Kuriyama, T., Izumi, T., Origasa, H., Giersbergen, P. L., Dingemanse, J. and Tanaka, S. (2005) Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ. J. 69, 131-137.   DOI
2 Seki, S., Kobayashi, M., Itagaki, S., Hirano, T. and Iseki, K. (2009) Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells. Biochim. Biophys. Acta 1788, 911-917.   DOI
3 Treiber, A., Schneiter, R., Hausler, S. and Stieger, B. (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Dispos. 35, 1400-1407.   DOI
4 van Giersbergen, P. L., Treiber, A., Schneiter, R., Dietrich, H. and Dingemanse, J. (2007) Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin. Pharmacol. Ther. 81, 414-419.   DOI
5 Wienkers, L. C. and Heath, T. G. (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 4, 825-833.   DOI
6 Williamson, B., Dooley, K. E., Zhang, Y., Back, D. J. and Owen, A. (2013) Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob. Agents Chemother. 57, 6366-6369.   DOI
7 Zhang, Z. H., Tang, J. H., Zhan, Z. L., Zhang, X. L., Wu, H. H. and Hou, Y. N. (2012) Cellular toxicity of isoniazid together with rifampicin and the metabolites of isoniazid on QSG-7701 hepatocytes. Asian Pac. J. Trop. Med. 5, 306-309.   DOI
8 Fujiwara, R., Takenaka, S., Hashimoto, M., Narawa, T. and Itoh, T. (2014) Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders. Sci. Rep. 4, 5251.
9 Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A. and Darst, S. A. (2001) Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 104, 901-912.   DOI
10 Dingemanse, J. and van Giersbergen, P. L. (2004) Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. 43, 1089-1115.   DOI
11 Kalliokoski, A. and Niemi, M. (2009) Impact of OATP transporters on pharmacokinetics. British journal of pharmacology 158, 693-705.   DOI
12 Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J. L., Green, B., Deng, H., Kaput, J. and Ning, B. (2011) Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab. Dispos. 39, 528-538.   DOI
13 Han, J. Y., Ahn, S. Y., Yoo, J. H., Nam, S. Y., Hong, J. T. and Oh, K. W. (2015) Alleviation of kainic acid-induced brain barrier dysfunction by 4-o-methylhonokiol in in vitro and in vivo models. Biomed Res. Int. 2015, 893163.
14 Jeong, H. U., Kwon, M., Lee, Y., Yoo, J. S., Shin, D. H., Song, I. S. and Lee, H. S. (2015) Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide. Drug Des. Devel. Ther. 9, 643-653.
15 Lin, J. H. and Lu, A. Y. (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Br. J. Pharmacol. 35, 361-390.
16 Perez, G., Tabares, B., Jover, R., Gomez-Lechon, M. J. and Castell, J. V. (2003) Semi-automatic quantitative RT-PCR to measure CYP induction by drugs in human hepatocytes. Toxicol. In Vitro 17, 643-649.   DOI
17 Menochet, K., Kenworthy, K. E., Houston, J. B. and Galetin, A. (2012) Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab. Dispos. 40, 1744-1756.   DOI
18 Ofotokun, I. (2005) Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes. Top. HIV Med. 13, 79-83.